CA-ARROW-ELECTRONICS
14.3.2023 09:02:14 CET | Business Wire | Press release
Arrow Electronics, Inc. and Qualcomm Technologies International, Ltd. have expanded their strategic collaboration. The establishment of Edge Labs — an Arrow Center of Excellence (CoE) — will help customers accelerate the development of connected intelligent edge devices based on solutions from Qualcomm Technologies.
Edge and AI solution development is becoming increasingly challenging to customers due to several factors such as lack of prior experience, limited access to high-performance edge and AI chipsets, supply chain complexity and fledgling ecosystem. Edge Labs aims to help innovators navigate these challenges while increasing the adoption of Edge AI using solutions from Qualcomm Technologies across security, safety, healthcare, robotics, cameras, displays, optical inspection and other IoT applications.
Edge Labs will have a dedicated solution architect and engineering team to develop application-specific solutions, including training sales and field application engineers specifically on Qualcomm Technologies’ products. It will also offer design services to enable lower risk and faster time to market for customers through eInfochips, an Arrow company.
“We are excited to expand our collaboration with Qualcomm Technologies and establish Edge Labs, an Arrow center of excellence,” said Kirk Schell, president of Arrow’s global components business. “Combining Arrow’s strength in engineering and supply chain with Qualcomm Technologies’ innovative products will help customers accelerate their design and speed to market in robotic, edge appliance and machine vision applications.”
Customers can rely on Edge Labs to deliver innovative and leading edge products, accelerate and de-risk design cycles, leverage the Aikri™ portfolio of SOMs and development kits, and get access to a world-class support team enabling them to plan and manage their product roadmap and lifecycles.
"Edge AI is the next big engineering frontier and we’re thrilled to expand our strategic collaboration with Arrow Electronics to strengthen the development and proliferation of IoT technologies and serve a more diverse and global customer base,” said Dev Singh, vice president, business development, Qualcomm Technologies, Inc. “Edge Labs CoE customers will have the ability to unlock new and unique edge AI use cases thanks to Qualcomm Technologies’ leading edge platforms and unified SW stack."
The first development kit from eInfochips as part of the Edge Labs initiative, “Aikri 42x”, based on Qualcomm QRB4210 SoC, has just launched and is being demonstrated at Embedded World conference, March 14-16, in Messe, Nuremberg, Germany.
To learn more and to collaborate with Edge Labs, visit Embedded World (Hall 3A.135), www.arrow.com/edgelabs and www.einfochips.com/edgelabs or edgelabs@arrow.com or edgelabs@einfochips.com.
About Arrow Electronics
Arrow Electronics guides innovation forward for over 210,000 leading technology manufacturers and service providers. With 2022 sales of $37 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com.
About eInfochips
eInfochips, an Arrow Electronics company, is a leading provider of digital transformation and product engineering services. With 500-plus products developed and 40 million deployments in 140 countries, eInfochips continues to fuel technological innovations in multiple verticals.
eInfochips accelerates time to market for its customers with its expertise in the areas of cloud, IoT, AI/ML, digital twins, hyper automation, and cybersecurity.
About Qualcomm
Qualcomm is enabling a world where everyone and everything can be intelligently connected. Our one technology roadmap allows us to efficiently scale the technologies that launched the mobile revolution — including advanced connectivity, high-performance, low-power compute, on-device intelligence and more — to the next generation of connected smart devices across industries. Innovations from Qualcomm and our family of Snapdragon platforms will help enable cloud-edge convergence, transform industries, accelerate the digital economy, and revolutionize how we experience the world, for the greater good.
Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering, research and development functions, and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005495/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
